{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:23:00Z","timestamp":1789435380011,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16467"],"award-info":[{"award-number":["19K16467"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K09907"],"award-info":[{"award-number":["24K09907"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11095-026-04082-8","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:11:54Z","timestamp":1774307514000},"page":"1551-1562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanistic Insights into pH-Responsive Drug Release and Antitumor Effects of an Albumin-Pirarubicin Conjugate"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4589-0842","authenticated-orcid":false,"given":"Kenji","family":"Tsukigawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotone","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Irie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tokuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kindness Lomotey","family":"Commey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-2367","authenticated-orcid":false,"given":"Keishi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"4082_CR1","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res Am Assoc Cancer Res. 1986;46:6387\u201392.","journal-title":"Cancer Res Am Assoc Cancer Res"},{"key":"4082_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136\u201351. https:\/\/doi.org\/10.1016\/j.addr.2010.04.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"4082_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1517\/17425247.2014.955011","volume":"12","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Fang J, Maeda H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv. 2015;12:53\u201364. https:\/\/doi.org\/10.1517\/17425247.2014.955011.","journal-title":"Expert Opin Drug Deliv"},{"key":"4082_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2022.09.007","volume":"351","author":"S Jeon","year":"2022","unstructured":"Jeon S, Jun E, Chang H, Yhee JY, Koh E-Y, Kim Y, et al. Prediction the clinical EPR effect of nanoparticles in patient-derived xenograft models. J Control Release. 2022;351:37\u201349. https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.007.","journal-title":"J Control Release"},{"key":"4082_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114614","volume":"191","author":"R Sun","year":"2022","unstructured":"Sun R, Xiang J, Zhou Q, Piao Y, Tang J, Shao S, et al. The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives. Adv Drug Deliv Rev. 2022;191:114614. https:\/\/doi.org\/10.1016\/j.addr.2022.114614.","journal-title":"Adv Drug Deliv Rev"},{"key":"4082_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114449","volume":"188","author":"Y Zi","year":"2022","unstructured":"Zi Y, Yang K, He J, Wu Z, Liu J, Zhang W. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Adv Drug Deliv Rev. 2022;188:114449. https:\/\/doi.org\/10.1016\/j.addr.2022.114449.","journal-title":"Adv Drug Deliv Rev"},{"key":"4082_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Sig Transduct Target Ther. 2023;8:293. https:\/\/doi.org\/10.1038\/s41392-023-01536-y.","journal-title":"Sig Transduct Target Ther"},{"key":"4082_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.addr.2009.10.004","volume":"62","author":"J Kope\u010dek","year":"2010","unstructured":"Kope\u010dek J, Kope\u010dkov\u00e1 P. HPMA copolymers: origins, early developments, present, and future\u2606. Adv Drug Deliv Rev. 2010;62:122\u201349. https:\/\/doi.org\/10.1016\/j.addr.2009.10.004.","journal-title":"Adv Drug Deliv Rev"},{"key":"4082_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ejpb.2008.11.010","volume":"71","author":"H Maeda","year":"2009","unstructured":"Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71:409\u201319. https:\/\/doi.org\/10.1016\/j.ejpb.2008.11.010.","journal-title":"Eur J Pharm Biopharm"},{"key":"4082_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/sj.gt.3302843","volume":"14","author":"H Hatakeyama","year":"2007","unstructured":"Hatakeyama H, Akita H, Kogure K, Oishi M, Nagasaki Y, Kihira Y, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 2007;14:68\u201377. https:\/\/doi.org\/10.1038\/sj.gt.3302843.","journal-title":"Gene Ther"},{"key":"4082_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.addr.2010.09.001","volume":"63","author":"H Hatakeyama","year":"2011","unstructured":"Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev. 2011;63:152\u201360. https:\/\/doi.org\/10.1016\/j.addr.2010.09.001.","journal-title":"Adv Drug Deliv Rev"},{"key":"4082_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jconrel.2012.11.017","volume":"165","author":"H Nakamura","year":"2013","unstructured":"Nakamura H, Liao L, Hitaka Y, Tsukigawa K, Subr V, Fang J, et al. Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo. J Control Release. 2013;165:191\u20138. https:\/\/doi.org\/10.1016\/j.jconrel.2012.11.017.","journal-title":"J Control Release"},{"key":"4082_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jconrel.2013.11.011","volume":"174","author":"H Nakamura","year":"2014","unstructured":"Nakamura H, Etrych T, Chytil P, Ohkubo M, Fang J, Ulbrich K, et al. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J Control Release. 2014;174:81\u20137. https:\/\/doi.org\/10.1016\/j.jconrel.2013.11.011.","journal-title":"J Control Release"},{"key":"4082_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","volume":"132","author":"F Kratz","year":"2008","unstructured":"Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132:171\u201383. https:\/\/doi.org\/10.1016\/j.jconrel.2008.05.010.","journal-title":"J Control Release"},{"key":"4082_CR15","doi-asserted-by":"publisher","first-page":"H1872","DOI":"10.1152\/ajpheart.1992.263.6.H1872","volume":"263","author":"JE Schnitzer","year":"1992","unstructured":"Schnitzer JE, Oh P. Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. Am J Physiol Heart Circ Physiol. 1992;263:H1872\u20139. https:\/\/doi.org\/10.1152\/ajpheart.1992.263.6.H1872.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4082_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1593\/tlo.09109","volume":"2","author":"N Desai","year":"2009","unstructured":"Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2:59\u201364. https:\/\/doi.org\/10.1593\/tlo.09109.","journal-title":"Transl Oncol"},{"key":"4082_CR17","doi-asserted-by":"publisher","first-page":"10557","DOI":"10.1002\/adma.201600038","volume":"28","author":"Q Chen","year":"2016","unstructured":"Chen Q, Liu Z. Albumin carriers for cancer theranostics: a conventional platform with new promise. Adv Mater. 2016;28:10557\u201366. https:\/\/doi.org\/10.1002\/adma.201600038.","journal-title":"Adv Mater"},{"key":"4082_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1040-8428(97)00015-2","volume":"26","author":"G Stehle","year":"1997","unstructured":"Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JCM, Hartung G, et al. Plasma protein (albumin) catabolism by the tumor itself\u2014implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26:77\u2013100. https:\/\/doi.org\/10.1016\/S1040-8428(97)00015-2.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4082_CR19","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1158\/0008-5472.CAN-17-0604","volume":"77","author":"M Chatterjee","year":"2017","unstructured":"Chatterjee M, Ben-Josef E, Robb R, Vedaie M, Seum S, Thirumoorthy K, et al. Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy. Cancer Res. 2017;77:5925\u201337. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0604.","journal-title":"Cancer Res"},{"issue":"16","key":"4082_CR20","first-page":"4373","volume":"49","author":"IF Tannock","year":"1989","unstructured":"Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49(16):4373\u201384.","journal-title":"Cancer Res"},{"issue":"1","key":"4082_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010022","volume":"14","author":"K Tsukigawa","year":"2020","unstructured":"Tsukigawa K, Imoto S, Yamasaki K, Nishi K, Tsutsumi T, Yokoyama S, et al. Synthesis and in vitro assessment of pH-sensitive human serum albumin conjugates of pirarubicin. Pharmaceuticals. 2020;14(1):22. https:\/\/doi.org\/10.3390\/ph14010022.","journal-title":"Pharmaceuticals"},{"key":"4082_CR22","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.7164\/antibiotics.32.1082","volume":"32","author":"H Umezawa","year":"1979","unstructured":"Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot. 1979;32:1082\u20134. https:\/\/doi.org\/10.7164\/antibiotics.32.1082.","journal-title":"J Antibiot"},{"key":"4082_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.7164\/antibiotics.36.312","volume":"36","author":"S Kunimoto","year":"1983","unstructured":"Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H. Rapid uptake by cultured tumor cells and intracellular behavior of 4\u2019-O-tetrahydropyranyladriamycin. J Antibiot. 1983;36:312\u20137. https:\/\/doi.org\/10.7164\/antibiotics.36.312.","journal-title":"J Antibiot"},{"key":"4082_CR24","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/aps.2012.20","volume":"33","author":"S Zheng","year":"2012","unstructured":"Zheng S, Xiong S, Lin F, Qiao G, Feng T, Shen Z, et al. Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2\/M phase cell cycle arrest. Acta Pharmacol Sin. 2012;33:832\u20138. https:\/\/doi.org\/10.1038\/aps.2012.20.","journal-title":"Acta Pharmacol Sin"},{"key":"4082_CR25","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.7164\/antibiotics.37.1697","volume":"37","author":"S Kunimoto","year":"1984","unstructured":"Kunimoto S, Miura K, Umezawa K, Xu C-Z, Masuda T, Takeuchi T, et al. Cellular uptake and efflux and cytostatic activity of 4\u2019-o-tetrahydropyranyladriamycin. J Antibiot Japan Antibiot Res Assoc. 1984;37:1697\u2013702. https:\/\/doi.org\/10.7164\/antibiotics.37.1697.","journal-title":"J Antibiot Japan Antibiot Res Assoc"},{"key":"4082_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1203\/00006450-200202000-00021","volume":"51","author":"E Koh","year":"2002","unstructured":"Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, Takahashi H. Apoptosis in young rats with adriamycin-induced cardiomyopathy\u2014comparison with pirarubicin, a new anthracycline derivative. Pediatr Res. 2002;51:256\u20139. https:\/\/doi.org\/10.1203\/00006450-200202000-00021.","journal-title":"Pediatr Res"},{"key":"4082_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1124\/jpet.107.132100","volume":"325","author":"N Katayama","year":"2008","unstructured":"Katayama N, Nakajou K, Komori H, Uchida K, Yokoe J, Yasui N, et al. Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug. J Pharmacol Exp Ther. 2008;325:69\u201376. https:\/\/doi.org\/10.1124\/jpet.107.132100.","journal-title":"J Pharmacol Exp Ther"},{"key":"4082_CR28","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1021\/acs.molpharmaceut.6b00697","volume":"13","author":"H Nakamura","year":"2016","unstructured":"Nakamura H, Koziolov\u00e1 E, Chytil P, Tsukigawa K, Fang J, Haratake M, et al. Pronounced cellular uptake of pirarubicin versus that of other anthracyclines: comparison of HPMA copolymer conjugates of pirarubicin and doxorubicin. Mol Pharm. 2016;13:4106\u201315. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00697.","journal-title":"Mol Pharm"},{"key":"4082_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jconrel.2016.07.017","volume":"237","author":"S Kikuchi","year":"2016","unstructured":"Kikuchi S, Kanoh D, Sato S, Sakurai Y, Suzuki M, Nakamura H. Maleimide-functionalized closo-dodecaborate albumin conjugates (MID-AC): unique ligation at cysteine and lysine residues enables efficient boron delivery to tumor for neutron capture therapy. J Control Release. 2016;237:160\u20137. https:\/\/doi.org\/10.1016\/j.jconrel.2016.07.017.","journal-title":"J Control Release"},{"key":"4082_CR30","doi-asserted-by":"publisher","first-page":"12587","DOI":"10.1039\/D1SC03311E","volume":"12","author":"H Schueffl","year":"2021","unstructured":"Schueffl H, Theiner S, Hermann G, Mayr J, Fronik P, Groza D, et al. Albumin-targeting of an oxaliplatin-releasing platinum(IV) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo. Chem Sci. 2021;12:12587\u201399. https:\/\/doi.org\/10.1039\/D1SC03311E.","journal-title":"Chem Sci"},{"key":"4082_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ma15155290","volume":"15","author":"Z Ren","year":"2022","unstructured":"Ren Z, Liao T, Li C, Kuang Y. Drug delivery systems with a \u201ctumor-triggered\u201d targeting or intracellular drug release property based on dePEGylation. Materials. 2022;15:5290. https:\/\/doi.org\/10.3390\/ma15155290.","journal-title":"Materials"},{"key":"4082_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/nsr\/nwx062","volume":"5","author":"L Feng","year":"2018","unstructured":"Feng L, Dong Z, Tao D, Zhang Y, Liu Z. The acidic tumor microenvironment: a target for smart cancer nano-theranostics. Natl Sci Rev. 2018;5:269\u201386.","journal-title":"Natl Sci Rev"},{"key":"4082_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201702858","volume":"14","author":"H Lu","year":"2018","unstructured":"Lu H, Stenzel MH. Multicellular tumor spheroids (MCTS) as a 3D in vitro evaluation tool of nanoparticles. Small. 2018;14:1702858. https:\/\/doi.org\/10.1002\/smll.201702858.","journal-title":"Small"},{"key":"4082_CR34","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1021\/acs.molpharmaceut.9b00248","volume":"16","author":"H Nakamura","year":"2019","unstructured":"Nakamura H, Koziolov\u00e1 E, Chytil P, Etrych T, Haratake M, Maeda H. Superior penetration and cytotoxicity of HPMA copolymer conjugates of pirarubicin in tumor cell spheroid. Mol Pharm. 2019;16:3452\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00248.","journal-title":"Mol Pharm"},{"key":"4082_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121242","volume":"12","author":"J Kudl\u00e1\u010dov\u00e1","year":"2020","unstructured":"Kudl\u00e1\u010dov\u00e1 J, Kotrchov\u00e1 L, Kostka L, Rand\u00e1rov\u00e1 E, Filipov\u00e1 M, Janou\u0161kov\u00e1 O, et al. Structure-to-efficacy relationship of HPMA-based nanomedicines: the tumor spheroid penetration study. Pharmaceutics. 2020;12:1242. https:\/\/doi.org\/10.3390\/pharmaceutics12121242.","journal-title":"Pharmaceutics"},{"key":"4082_CR36","doi-asserted-by":"publisher","unstructured":"Shi Z, Luo M, Huang Q, Ding C, Wang W, Wu Y, et al. NIR-dye bridged human serum albumin reassemblies for effective photothermal therapy of tumor. Nat Commun. Nature Publishing Group; 2023;14:6567. https:\/\/doi.org\/10.1038\/s41467-023-42399-9","DOI":"10.1038\/s41467-023-42399-9"},{"key":"4082_CR37","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1039\/c7tb02902k","volume":"5","author":"H Lu","year":"2017","unstructured":"Lu H, Noorani L, Jiang Y, Du AW, Stenzel MH. Penetration and drug delivery of albumin nanoparticles into pancreatic multicellular tumor spheroids. J Mater Chem B. 2017;5:9591\u20139. https:\/\/doi.org\/10.1039\/c7tb02902k.","journal-title":"J Mater Chem B"},{"key":"4082_CR38","doi-asserted-by":"publisher","unstructured":"Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, et al. Blood\u2013brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano. 2016;10:9999\u201310012. https:\/\/doi.org\/10.1021\/acsnano.6b04268.","DOI":"10.1021\/acsnano.6b04268"},{"key":"4082_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jconrel.2015.08.055","volume":"219","author":"AM Al-Abd","year":"2015","unstructured":"Al-Abd AM, Aljehani ZK, Gazzaz RW, Fakhri SH, Jabbad AH, Alahdal AM, et al. Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. J Control Release. 2015;219:269\u201377. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.055.","journal-title":"J Control Release"},{"key":"4082_CR40","doi-asserted-by":"publisher","first-page":"596","DOI":"10.11553\/antibiotics1968b.39.596","volume":"39","author":"H Tone","year":"1986","unstructured":"Tone H, Kiyosaki T, Shirai M. Effect of (2\"R)-4\u2019-O-tetrahydropyranyladriamycin, a new antitumor antibiotic, on the bone marrow function of rabbits. Jpn J Antibiot. 1986;39:596\u2013611. https:\/\/doi.org\/10.11553\/antibiotics1968b.39.596.","journal-title":"Jpn J Antibiot"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04082-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:30:44Z","timestamp":1781537444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04082-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4082"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04082-8","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}